Apollomics, Inc. Price & Performance (APLM)

Apollomics, Inc. (NASDAQ:APLMW) has seen a further decrease in short interest, dropping 20.5% between mid-February and the end of the month. Despite this, its stock remains stagnant at $0.01, reflecting ongoing struggles. The company’s 12-month high of $0.03 highlights the extent of its challenges in maintaining investor confidence.12

Maxpro Capital Acquisition Corp. (APLM) has reached a 52-week low of $6.2, marking a 91.23% decline over the past year. This drop reflects broader financial struggles, including disappointing trial results for its drug candidate uproleselan. The company is shifting focus to vebreltinib, its lead program targeting advanced tumors.3

Vaxart has announced a 10% workforce reduction following a halted vaccine trial, while Elevation Oncology is cutting 70% of its staff after discontinuing a key drug program. These layoffs underscore the financial pressures and strategic pivots many biotechs are facing in a challenging market environment.4